Statement of Comprehensive Income
Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Paying users area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Cash Flow Statement
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Comprehensive income item | Description | The company |
---|---|---|
Net earnings (loss) attributable to BMS | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level. |
Comprehensive income (loss) attributable to BMS | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners. | Bristol-Myers Squibb Co. comprehensive income (loss) attributable to BMS decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level. |